Brexin Tablets are indicated for the treatment of actuate painful inflammatory conditions. It is a relatively new formulation of Piroxicam as a complex with β-cyclodextrin. Keep reading to discover how it works and why Brexin Tablets are superior to Piroxicam alone.
Braxin Vs Plain Piroxicam
β-cyclodextrin in Brexin has a particular chemical structure that enables it to form inclusion compounds (molecular encapsulation) with various drugs. This results in an increased bioavailability by improving solubility and stability. After oral administration, Brexin has a quicker absorption as compare to Piroxicam alone because it is highly soluble in water. This rapid absorption leads to a faster increase in plasma levels and Bexin achieves peak plasma concentration much earlier than plain Piroxicam. In other words (or in clinical terms), Brexin has a more potent analgesic and anti-inflammatory effect as compare to plain Piroxicam.
Recommended Dosage of Brexin Tablets
The half-life of Brexin Tablets is same as plain Piroxicam, which is longer than the most NSAIDs. The recommended dosage is just one Brexin Tablet once daily. This makes it a suitable treatment option for rheumatic and inflammatory disorders with painful symptoms.
Brexin – Important Warning
If you are experiencing painful inflammatory conditions that are affecting your normal day-to-day activities, Brexin Tablets may be a good option for you. But it is strongly recommended to ask a qualified healthcare professional (your physician) if treatment with Brexin is right for you. In order to avoid possible Side Effects, do not take Brexin Tablets or any other medicine without a prescription.
Brexin – Precautions
In patients with a medical history of upper Gastrointestinal disturbances Brexin Tablets must be used under strict medical control. Particular caution must be taken in subjects with cardiocirculatory insufficiency, arterial hypertension, reduced hepatic or renal function, previous or current blood alterations, bronchial asthma and elderly patients. Brexin Tablets (and plain Piroxicam) may affect concentration and it is therefore not advisable to drive or undertake any activity requiring quick reflex action.
Brexin tablets may increase BUN (blood urea nitrogen) in some patients. However, BUN does not keep on increasing as the therapy with Brexin continues, but reaches a steady level which goes back to or towards the norm on discontinuing the treatment. The increase of BUN is not associated with an increase of serum creatinine. Brexin, plain Piroxicam and other NSAIDs, decrease platelet aggregation and prolong bleeding. This should be remembered when hematological tests are carried out and when patients undergo concomitant treatment with drugs that inhibit platelet aggregation.